Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression
- PMID: 17050671
- DOI: 10.1158/1541-7786.MCR-06-0077
Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression
Abstract
Heterogeneous expression of melanocytic antigens occurs frequently in melanomas and represents a potent barrier to immunotherapy. We previously showed that coordinated losses of several melanocytic antigens are generally attributable to down-regulation of antigen gene expression rather than irreversible mutation. Treatment of melanoma cells with mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitors blocks ERK activation and increases steady-state levels of mRNAs and corresponding protein expression for the melanocytic antigens Melan-A/MART-1, gp100, and tyrosinase. Although the degree of MEK inhibitor enhancement of antigen expression varied among different cell lines irrespective of their antigen expression status, all showed detectable responses. Notably, the antigen-enhancing effects of the MEK inhibitors could not be attributed to the master melanocytic regulator MITF-M. Because MAPK pathway activation via constitutively active mutant forms of BRAF is common in melanomas, correlation between BRAF function and antigen expression was investigated. No simple correlation of endogenous BRAF mutational status and antigen levels was observed, but transient overexpression of V600E BRAF increased ERK activation and reduced Melan-A/MART-1 levels in antigen-positive cell lines. These data indicate that whereas multiple factors may regulate antigen expression in melanomas, enhancement of MAPK signaling can act as a negative influence. Blocking such signaling with MEK inhibitors accordingly augments antigen levels, thereby enhancing Melan-A/MART-1-specific cytotoxic T-cell responses to antigen-negative cells following MEK inhibition treatment. Consequently, MAPK inhibition may assist targeting of melanomas for immunotherapy.
Similar articles
-
Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.Clin Cancer Res. 2007 Feb 15;13(4):1341-9. doi: 10.1158/1078-0432.CCR-06-1753. Clin Cancer Res. 2007. PMID: 17317846
-
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Cancer Res. 2004 Aug 15;64(16):5556-9. doi: 10.1158/0008-5472.CAN-04-1669. Cancer Res. 2004. PMID: 15313890
-
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.Cancer Res. 2010 Jul 1;70(13):5213-9. doi: 10.1158/0008-5472.CAN-10-0118. Epub 2010 Jun 15. Cancer Res. 2010. PMID: 20551059
-
BRAF somatic mutations in malignant melanoma and melanocytic naevi.Melanoma Res. 2006 Apr;16(2):97-103. doi: 10.1097/01.cmr.0000215035.38436.87. Melanoma Res. 2006. PMID: 16567964 Review.
-
Melanoma therapy: Check the checkpoints.J Dermatol. 2016 Feb;43(2):121-4. doi: 10.1111/1346-8138.13257. J Dermatol. 2016. PMID: 26813076 Review.
Cited by
-
Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.Int Immunol. 2016 Aug;28(8):393-9. doi: 10.1093/intimm/dxw030. Epub 2016 Jul 8. Int Immunol. 2016. PMID: 27401477 Free PMC article. Review.
-
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.J Immunother Cancer. 2018 Jul 27;6(1):76. doi: 10.1186/s40425-018-0387-x. J Immunother Cancer. 2018. PMID: 30053905 Free PMC article. Clinical Trial.
-
Immune system and melanoma biology: a balance between immunosurveillance and immune escape.Oncotarget. 2017 Oct 31;8(62):106132-106142. doi: 10.18632/oncotarget.22190. eCollection 2017 Dec 1. Oncotarget. 2017. PMID: 29285320 Free PMC article. Review.
-
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.Pigment Cell Melanoma Res. 2015 Jul;28(4):390-406. doi: 10.1111/pcmr.12370. Epub 2015 Apr 17. Pigment Cell Melanoma Res. 2015. PMID: 25818589 Free PMC article. Review.
-
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.Cancer Immunol Immunother. 2011 Jan;60(1):133-44. doi: 10.1007/s00262-010-0926-x. Epub 2010 Oct 30. Cancer Immunol Immunother. 2011. PMID: 21052994 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous